SlideShare a Scribd company logo
ANTIBIOTICS
2015 IN ICU
SAMIR EL ANSARY
https://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY
CriticalCare Antibiotics
Definitions
• Minimum Inhibitory Concentration
– Antimicrobial concentration that inhibits visible
microbial growth in artificial media
• Gram Stain
– Gram positive
– Gram negative
• Acid fast
• Problems with MIC:
•Fixed drug concentration
•All or none parameter. Growth vs. no growth
•Does not provide information on the time course of
antimicrobial activity
•Drug concentrations change throughout the dosing
interval
•Does not capture interpatient pharmacokinetic
variability
•Does not provide info on post-antibiotic effects
Gram staining
FOR differentiating bacterialspecies into (gram-
positive and gram-negative).
The name comes from its inventor, Hans Christian
Gram.
Gram staining differentiates bacteria by the chemical
and physical properties of their cell walls by
detecting peptidoglycan, which is present in a thick
layer in gram-positive bacteria.
Gram staining
In a Gram stain test, gram-positive bacteria retain
the crystal violet dye, while a counterstain
(commonly safranin or fuchsine) added after
the crystal violet gives all gram-negative
bacteria a red or pink coloring.
Acid-fastness
A physical property of certain bacteria (and, less
commonly, protozoa), specifically their resistance to
decolorization by acids during staining procedures.
The high mycolic acid content of certain Protozoa cell
walls, and those of Mycobacteria, is responsible for
the staining pattern of poor absorption followed by
high retention. Usually used to identify
mycobacteria.
Pharmacodynamics
Time Dependent Killing
• Beta-Lactams
– Penicillin
– Cephalosporins
– Piperacillin-Tazobactam
– Carbapenems
• Meropenem
• Ertapenem
• Pharmacokinetics versus
pharmacodynamics
•Pharmacokinetics mathematically describe the
relationship of antibiotic concentration to time.
• Aabsorption, distribution, metabolism, elimination,
half-life, volume of distribution, and area under the
concentration-time curve (AUC).
•Pharmacodynamics
•Describe the relationship of antibiotic concentration
to pharmacologic effect or microorganism death.
• The three main pharmacodynamic parameters that
are used are the
• peak to minimal inhibitory concentration ratio
(peak/MIC), the AUC to MIC ratio (AUC/MIC)
•Pharmacodynamics
• The time the drug concentration remains
above the MIC (T>MIC).
• Concentration independent antimicrobials include: beta-
lactams, vancomycin, macrolides, aztreonam, carbapenems,
clindamycin, tetracyclines, quinupristin/dalfopristin,
flucytosine, and azole antifungals.
Pharmacodynamics
Concentration Dependent Killing
• Fluoroquinolones
– Levofloxacin
– Ciprofloxacin
– Moxifloxacin
• Aminoglycosides
– Amikacin
– Tobramycin
– Gentamicin
Pharmacodynamics
AUC/MIC Dependent Killing
• Vancomycin
• Linezolid
• Clindamycin
• Macrolides
– Azithromycin
– Clarithromycin
– Erythromycin
Keys to Success
• Antibiotic covers potential infection/bacteria
• Dose of antibiotic is appropriate for treatment
of infection and adjusted for renal/hepatic
impairment
• Antibiotic penetrates site of infection
• Antibiotic is being absorbed
• Adequate treatment duration
Risk Factors for Resistance
• Antimicrobial therapy in the preceding 90 days
• Current hospitalization of 5 days or more
• High resistance rates in the unit
• Residence in a nursing home or extended care facility
• Immunocompromised
• Home wound care
• Chronic dialysis
Gram Positive Agents
Vancomycin
Linezolid
Daptomycin
Gram Positive Bacteria
• Cocci
– Staphylococcus
• S. aureus
• S. epidermidis
– Streptococcus
• S. pyogenes (Group A)
• S. viridians
• S. pneumoniae
– Enterococcus
• E. faecalis
• E. Faecium
• Bacilli
– Listeria monocytogenes
– Bacillus anthracis
– Corynebacterium species
– Proprionibacterium acnes
Vancomycin
• Spectrum of activity
– Staph (MRSA, MSSA), strep, enterococcus, c. difficile colitis (oral)
• Mechanism of action
– Inhibits synthesis of peptidoglycan/bacterial cell wall formation
• Dosing
– Actual body weight
– Loading dose = 25-30 mg/kg
– Maintenance dose = 15-20 mg/kg
– Usual Frequency = every 8-24h
– Adjust dose for renal impairment
Vancomycin
• Adverse effects
– Redman syndrome
– Thrombocytopenia
– Possible nephrotoxicity ??
– Ototoxicity (rare) Ototoxicity is not associated with trough
concentrations.
• Monitoring
– Goal Trough = 15-20 mcg/mL
– Bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia
– Initial: trough before 4th or 5th dose
– Maintenance: trough once weekly
Vancomycin with Dialysis
• Continuous renal replacement therapy (CRRT)
– 15mg/kg q24h
– Hold dose if CRRT stopped > 8h
– Trough before 4th or 5th dose
• Intermittent hemodialysis (iHD)
– Pulse dosing with iHD
– iHD removes ~25% of vancomycin
– Goal Pre-iHD level < 24 mcg/mL
– Initial dose = 15mg/kg x1 dose
– Maintenance dose based on pre-iHD levels
Linezolid
• Spectrum of activity
– Staph (MSSA, MRSA), strep, VRE
• Mechanism of action
– Binds to bacterial ribosomes to inhibit protein
synthesis
• Bacteristatic against staph, vre but cidal
against strep pneumon
• Time dependent killing
Linezolid
• Adverse Effects
– Myelosupression (pancytopenia, thrombocytopenia)
– GI upset
– Serotonin syndrome
• Drug interactions
– Monoamine oxidase inhibitors (MAOI’s)
– Selective serotonin reuptake inhibitors (SSRI’s)
• Dosing
– 600mg IV/PO q12h
Linezolid
• Clinical Pearls
– May be used for vancomycin failure or intolerance
– Oral & IV formulations
– Bacteriostatic
– No renal adjustment
– May have prescribing restrictions
– Expensive
Daptomycin
• Spectrum of activity
– Staph (MSSA, MRSA), strep, enterococcus (VRE)
• Mechanism of action
– Causes bacterial membranes to depolarize leading to inhibition of
protein, DNA, and RNA synthesis
• Typical Dosing
– Adjust with renal impairment
– 4-6 mg/kg (actual weight) q24-48h
• Adverse Effects
– Arthralgia
– Myalgia
– CPK elevations
Daptomycin
• Clinical Pearls
– Not for treatment of pneumonia
– Can use doses of 8-10 mg/kg for severe infections
– Monitor CPK at baseline and weekly
– Can falsely elevate INR
– May have prescribing restrictions
– Takes 30-60 minutes to reconstitute
– Expensive
Gram Negative Agents
Aminoglycosides
Aztreonam
Gram Negative Bacteria
Cocci
• Neisseria gonorrhoeae
• Neisseria meningitidis
• Moraxella catarrhalis
Bacilli
• Pseudomonas aeruginosa
• Acinetobacter species
• Citrobacter species
• Enterobacter species
• Klebsiella pneumoniae
• E. Coli
• H. influenzae
• Proteus mirabilis
• S. maltophilia
https://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY
Aminoglycosides
• Spectrum of activity
– Only gram negative, gram positive synergy
• Mechanism of action
– Bind bacterial ribosome and inhibit protein synthesis
• Adverse effects
– Nephrotoxicity
– Ototoxicity
– Prolonged neuromuscular blockade
Medications
Gentamicin Tobramycin Amkicacin
• Aminoglycoside antibiotics possess
nondepolarizing neuromuscular blocking
activity, which is additive or synergistic with
the effects of the nondepolarizing
neuromuscular blocking agents used in
anesthesia .
• Aminoglycosides cause presynaptic inhibition
of acetylcholine release and postsynaptic
reduction in sensitivity
Aminoglycosides
• Clinical Pearls
– Used for
• Nosocomial infections
• Double gram negative coverage
• Endocarditis (synergy)
– Two dosing schemes
• Traditional dosing
• Extended interval dosing/once daily dosing
– Levels must be monitored
• Traditional = peak & trough around 3rd dose
• Extended interval = trough before 2nd dose
– Monitor Scr daily
Aztreonam
• Class
– Monobactam
• Spectrum of activity
‒ Gram positive: none
‒ Gram negative: most, except S. maltophilia
• Mechanism of action
– Inhibit cell wall synthesis
• Dosing
– Usual: 1-2g IV Q8h
– Meningitis: 2g IV Q6-8h
• Adverse effects (rare)
– Transient eosinophilia
– LFT elevations
– Thrombocytopenia
**Can be used with
penicillin allergy**
Mixed Spectrum Agents
Cephalosporins
Piperacillin-Tazobactam
Carbapenems
Spectrum of Activity Primary Use
First Generation
Cefazolin (Ancef) (IV)
Cephalexin (Keflex) (PO)
• Simple Gram (+) , simple gram (-) , no
anaerobes. No ceph gets enterococci.
• Simple SSTI, surgical prophylaxis
Second Generation
Cefotetan (Cefotan) (IV)
Cefoxitin (Mefoxin) (IV)
Cefuroxime (Ceftin) (IV)
Cefaclor (Ceclor) (PO)
Cefprozil (Cefzil) (PO)
• Same spectrum as 1st Generation
• Cefotetan and Cefoxitin cover anaerobes
• Surgical prophylaxis if anaerobes,
URTI, UTI
Third Generation
Ceftriaxone (Rocephin) (IV)
Cefotaxime (Claforan) (IV)
Ceftazadime (Fortaz) (IV)
Cefpodoxime (Vantan) (PO)
Cefdinir (Omnicef) (PO)
Cefixime (Suprax) (PO)
• Better gram (-)
• Ceftazadime-pseudomonas • PNA, meningitis
Fourth Generation
Cefepime (Maxipime) (IV)
• Good gram (+), nosocomial gram (-)
including pseudomonas
• No anaerobes
• Sepsis, HAP, neutropenic fever
Fifth Generation
Ceftaroline (Teflaro)
• MRSA, MSSA, E. faecalis, s.pneumoniae,
• Some gram (-), NO pseudomonas
• Pneumonia, SSTI
Cephalosporins
• CABP pathogens, ceftaroline has activity
against the Gram-positive organisms S.
pneumoniae, S. aureus and Streptococcus
pyogenes, and Gram-negative species
(Haemophilus influenzae and CABP
pathogens, ceftaroline has activity against the
Gram-positive organisms S. pneumoniae, S.
aureus and Streptococcus pyogenes, and
Gram-negative species .
Cephalosporins
• Clinical Pearls
– Do not cover enterococcus (except ceftaroline)
– ↑ gram negative coverage with higher generations
– Used for surgical prophylaxis
– Anaerobic coverage
• Cefoxitin
• Cefotetan
– Pseudomonas coverage
• Ceftazidime
• Cefepime
Fluoroquinolines
Medications
Ciprofloxaci
n
Levofloxacin Moxifloxacin
Gemifloxaci
n
Mechanism
of Action
Inhibit DNA gyrase and topoisomerase IV inhibiting DNA synthesis
Spectrum of
Activity
• Gram Negative: Enterobacteriaceae, Haemophilus spp,
Neisseria spp and M. Catarrhalis
• Atypicals
Pseudomonas
Pseudomonas
S. pneumoniae
Anaerobes
S. pneumoniae
- - -
Clinical Use
Gram (-)
infections,
Bone/Joint
PNA, UTI
PNA
NOT: UTI
PNA
Piperacillin-Tazobactam
• Spectrum of activity
– Gram negative: P. aeruginosa, Enterbacteriaceae
– Gram positive: MSSA, Enterococci, Strep
– Anaerobes
• Mechanism of action
– Inhibit cell wall synthesis
• Adverse effects
– Gastrointestinal intolerance
– C. difficle colitis
– Interstitial nephritis
• Mechanism of Action:
•Inhibit mucopeptide synthesis in the bacterial cell
wall, thus results in formation of defective cell walls
and osmotically unstable organisms susceptible to cell
lysis
•Tazobactam acts as a beta-lactamase inhibitor and
inactivates both plasmid and chromosome mediated
beta-lactamases
Carbapenems
Meropenem
(Merem®)
Ertapenem
(Invanz®)
Imipenem -
Cilastatin
(Primaxin®)
Doripenem
(Doribax®)
Mechanism of
Action
Inhibit cell wall synthesis
Spectrum of
Activity
Broad Spectrum: Gram (+), Gram (-), ESBL, Anaerobes
NOT: MRSA
--
NOT: Pseudomonas,
Enterococcus,
Acinetobacter
-- --
Adverse Effects
↓ Platelets
Drug Fever
Seizure
↓ Platelets
Drug Fever
Common Use Meningitis Intra-abdominal Nocardia NOT: Pneumonia
Carbapenems
• Clinical Pearls
– First line agent for extended spectrum beta-lactamase
(ESBL) producing bacteria
– Extended infusion meropenem
• ↑ time above MIC
– Reserved for severe infections
– May have prescribing restrictions
Tigecycline
• Spectrum of activity
– Enterococcus (including VRE), MSSA, MRSA, MRSE, anaerobes
– Not pseudomonas, proteus, providencia
• Mechanism of action
– Binds to bacterial ribosomes to inhibit protein synthesis
• Dose
– 100mg IV x 1 dose
– 50mg IV q12h
• Adverse effects
– Nausea and vomiting
– Hyperbiliruminemia
•Tigecycline has a spectrum of activity
that includes anaerobes, many gram-
positive cocci and gram-negative
bacilli w/ the exception of
Pseudomonas, Proteus, and
Providencia.
•N/V may occur in up to 2/3rds of
patients
Tigecycline
• Clinical Pearls
– No renal adjustment
– Hepatic dose adjustment (Child Pugh C)
• 100mg IV x 1, then 25mg IV Q12h
– Used for resistant infections
– Do not use for
• Ventilator associated pneumonia
• Bacteremia
– Can be used for
• Intra-abdominal infections
• Skin & soft tissue infections
•All-cause Mortality:
•An increase in all-cause mortality has been observed
•The cause of this mortality risk difference has not
been established.
•Tigecycline should be reserved for use in situations
when alternative treatments are not suitable.
•Death resulted from progression of infection
•Especially in ventilator associated pneumonia
•Reserve for use when other agents are not an
option
Atypical Agents
Fluoroquinolones
Macrolides
Tetracyclines
Atypical Bacteria
Agents
• Fluoroquinolones
– Levofloxacin
– Ciprofloxacin
– Moxifloxacin
– Gemifloxacin
• Macrolides
– Azithromycin
– Erythromycin
– Clarithromycin
• Tetracyclines
– Tetracycline
– Doxycycline
– Minocycline
Bacteria
• Mycoplasma
• Legionella pneumoniae
• Chlamydia pneumoniae
• Richettsia
• Actinomyces
Commonly EncounteredInfectiousDisease
Issues
Clostridium Difficile
Antimicrobials per IDSA Guidelines
Clostridium Difficile
• IDSA Recommendations
– No probiotics - ↑ Bloodstream infections
– Stop causative antimicrobials
– Repeat testing during the same episode is discouraged
– Vancomycin taper after second reoccurrence
– Dual antimicrobials
• Ileus = IV metronidazole + vancomycin enema
**PO vancomycin is only used to treat c. diff infection**
• There is no evidence to support administration of
combination therapy to patients with uncomplicated
CDI.
• Although hampered by its low statistical power, a
recent trial did not show any trend toward better
results
when rifampin was added to a metronidazole
regimen.
• There is no evidence to support use of a combination
of oral metronidazole and oral vancomycin.
Allergic Reactions
• IgE reactions
– Anaphylaxis
– Bronchospasm
– Angioedema
– Pruritic rash
– Uticaria
– Hypotension
Penicillin Allergy
Avoid Use
Incidence of
Reaction
May Use
Cephalosporins
• 1st/2nd generation
cephalosporin
2% • Aztreonam
• 3rd/4th generation
cephalosporin
Carbapenems
• None? 0-11% • All carbapenems?
• Aztreonam
• Graded challenge or PCN
skin test
•Penicillin-cephalosporin cross-reactivity studies that
confirmed penicillin allergy by skin testing are superior
in design compared with those that diagnosed
penicillin allergy by history alone.
•Another group of studies evaluated patients with
positive penicillin skin tests (to penicilloyl polylysine
[PPL], penicillin G, and/or the minor determinant
mixture [MDM]) who were challenged with
cephalosporins and found an overall reaction rate of
3.4 percent .
•If this analysis is limited to studies published after
1980 (when cephalosporins were no longer
contaminated with penicillin), the reaction rate is
reduced to 2 percent.
•Thus, approximately 2 percent of patients with skin-
test proven sensitivity to penicillin can be expected to
react to cephalosporins.
•Range for cephalosporin reaction was 0-12% reported
in the literature.
Treatment Approach
GOOD LUCK
SAMIR EL ANSARY
ICU PROFESSOR
AIN SHAMS
CAIRO
elansarysamir@yahoo.com
Global Critical Care
https://www.facebook.com/groups/1451610115129555/#!/groups/145
1610115129555/
Wellcome in our new group ..... Dr.SAMIR EL ANSARY

More Related Content

What's hot

FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptxFLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
Ankit Gajjar
 
Endotracheal intubation
Endotracheal intubationEndotracheal intubation
Endotracheal intubation
Ubaidur Rahaman
 
CABG on CARDIOPULMONARY BYPASS
CABG on CARDIOPULMONARY BYPASS  CABG on CARDIOPULMONARY BYPASS
CABG on CARDIOPULMONARY BYPASS
Shekhar Anand
 
Perioperative management of Jehovah's Witnesses
Perioperative management of Jehovah's WitnessesPerioperative management of Jehovah's Witnesses
Perioperative management of Jehovah's Witnesses
Arjuna Samaranayaka
 
COPD Exacerbations: Significance, Assessment, and Current Management
COPD Exacerbations:Significance, Assessment, and Current ManagementCOPD Exacerbations:Significance, Assessment, and Current Management
COPD Exacerbations: Significance, Assessment, and Current Management
Dr.Mahmoud Abbas
 
Renal transplant: anaesthetic implications & considerations
Renal transplant: anaesthetic implications & considerationsRenal transplant: anaesthetic implications & considerations
Renal transplant: anaesthetic implications & considerations
drsandeepbmore
 
ABGs interpritation and approach.ppt
ABGs interpritation and approach.pptABGs interpritation and approach.ppt
ABGs interpritation and approach.ppt
DIPAK PATADE
 
Continuous renal replacement therapy in icu Crrt 2
 Continuous renal replacement therapy in icu Crrt  2 Continuous renal replacement therapy in icu Crrt  2
Continuous renal replacement therapy in icu Crrt 2
samirelansary
 
Laryngeal mask-airway
Laryngeal mask-airwayLaryngeal mask-airway
Laryngeal mask-airway
Harith Daggupati
 
Atracurium
AtracuriumAtracurium
Atracurium
Farwa Shabbir
 
Caring Central Venous Access Device in Hematology
Caring Central Venous Access Device in HematologyCaring Central Venous Access Device in Hematology
Caring Central Venous Access Device in Hematology
Pritish Chandra Patra
 
CO2 absorbents and waste gas scavenging system.pptx
CO2 absorbents and waste gas scavenging system.pptxCO2 absorbents and waste gas scavenging system.pptx
CO2 absorbents and waste gas scavenging system.pptx
MCOMS
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
Ramachandra Barik
 
Traumatic brain injury-- anaesthetic implication
Traumatic brain injury-- anaesthetic implicationTraumatic brain injury-- anaesthetic implication
Traumatic brain injury-- anaesthetic implication
ZIKRULLAH MALLICK
 
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRANVENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRANimran80
 
Atracurium Vecuronium Pancuronium
Atracurium Vecuronium PancuroniumAtracurium Vecuronium Pancuronium
Atracurium Vecuronium Pancuronium
Ranjith Thampi
 
Neonatal and paediatric anaesthesia
Neonatal and paediatric anaesthesiaNeonatal and paediatric anaesthesia
Neonatal and paediatric anaesthesia
Shoaib Kashem
 
supraglottic airway devices
supraglottic airway devicessupraglottic airway devices
supraglottic airway devices
ZIKRULLAH MALLICK
 

What's hot (20)

ABG
ABGABG
ABG
 
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptxFLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
FLUID THERAPY AND ELECTROLYTE MANAGEMENT final.pptx
 
Endotracheal intubation
Endotracheal intubationEndotracheal intubation
Endotracheal intubation
 
CABG on CARDIOPULMONARY BYPASS
CABG on CARDIOPULMONARY BYPASS  CABG on CARDIOPULMONARY BYPASS
CABG on CARDIOPULMONARY BYPASS
 
Perioperative management of Jehovah's Witnesses
Perioperative management of Jehovah's WitnessesPerioperative management of Jehovah's Witnesses
Perioperative management of Jehovah's Witnesses
 
Propofol
PropofolPropofol
Propofol
 
COPD Exacerbations: Significance, Assessment, and Current Management
COPD Exacerbations:Significance, Assessment, and Current ManagementCOPD Exacerbations:Significance, Assessment, and Current Management
COPD Exacerbations: Significance, Assessment, and Current Management
 
Renal transplant: anaesthetic implications & considerations
Renal transplant: anaesthetic implications & considerationsRenal transplant: anaesthetic implications & considerations
Renal transplant: anaesthetic implications & considerations
 
ABGs interpritation and approach.ppt
ABGs interpritation and approach.pptABGs interpritation and approach.ppt
ABGs interpritation and approach.ppt
 
Continuous renal replacement therapy in icu Crrt 2
 Continuous renal replacement therapy in icu Crrt  2 Continuous renal replacement therapy in icu Crrt  2
Continuous renal replacement therapy in icu Crrt 2
 
Laryngeal mask-airway
Laryngeal mask-airwayLaryngeal mask-airway
Laryngeal mask-airway
 
Atracurium
AtracuriumAtracurium
Atracurium
 
Caring Central Venous Access Device in Hematology
Caring Central Venous Access Device in HematologyCaring Central Venous Access Device in Hematology
Caring Central Venous Access Device in Hematology
 
CO2 absorbents and waste gas scavenging system.pptx
CO2 absorbents and waste gas scavenging system.pptxCO2 absorbents and waste gas scavenging system.pptx
CO2 absorbents and waste gas scavenging system.pptx
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Traumatic brain injury-- anaesthetic implication
Traumatic brain injury-- anaesthetic implicationTraumatic brain injury-- anaesthetic implication
Traumatic brain injury-- anaesthetic implication
 
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRANVENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
VENTILATOR ASSOCIATED PNEUMONIA BY DR IMRAN
 
Atracurium Vecuronium Pancuronium
Atracurium Vecuronium PancuroniumAtracurium Vecuronium Pancuronium
Atracurium Vecuronium Pancuronium
 
Neonatal and paediatric anaesthesia
Neonatal and paediatric anaesthesiaNeonatal and paediatric anaesthesia
Neonatal and paediatric anaesthesia
 
supraglottic airway devices
supraglottic airway devicessupraglottic airway devices
supraglottic airway devices
 

Viewers also liked

Principles of Antibiotic Use in ICU
Principles of Antibiotic Use in ICUPrinciples of Antibiotic Use in ICU
Principles of Antibiotic Use in ICU
rksisodia
 
Clindamycin
ClindamycinClindamycin
Clindamycin
Shifa-At-Ara Zhizhi
 
Antibiotic update in icu
Antibiotic update in icuAntibiotic update in icu
Antibiotic update in icu
Dr. Mohamed Maged Kharabish
 
Guidelines for antibiotic use in icu
Guidelines for  antibiotic use in icuGuidelines for  antibiotic use in icu
Guidelines for antibiotic use in icu
Mahmod Almahjob
 
Antibiotic principles
Antibiotic principlesAntibiotic principles
Antibiotic principlesK.J Mokori
 
Clindamycin
ClindamycinClindamycin
Clindamycin
Dr Randy Chance
 
New generation Antibiotics /certified fixed orthodontic courses by Indian den...
New generation Antibiotics /certified fixed orthodontic courses by Indian den...New generation Antibiotics /certified fixed orthodontic courses by Indian den...
New generation Antibiotics /certified fixed orthodontic courses by Indian den...
Indian dental academy
 
Detection of inducible and constitutive clindamycin resistance among Staphylo...
Detection of inducible and constitutive clindamycin resistance among Staphylo...Detection of inducible and constitutive clindamycin resistance among Staphylo...
Detection of inducible and constitutive clindamycin resistance among Staphylo...
Dr Muktikesh Dash, MD, PGDFM
 
Antibiotics
AntibioticsAntibiotics
Antibiotics
Dr. Armaan Singh
 
Ppt penggunaan antibiotik yang bijaksana
Ppt penggunaan antibiotik yang bijaksanaPpt penggunaan antibiotik yang bijaksana
Ppt penggunaan antibiotik yang bijaksanaMahesa Suryanagara
 
Brain death in ICU
Brain death in ICUBrain death in ICU
Brain death in ICU
Sherif Elbadrawy
 
Optimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICUOptimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICU
Yazan Kherallah
 
Sepsis seminar final
Sepsis seminar   finalSepsis seminar   final
Sepsis seminar final
pulmonary medicine
 
sepsis new guidelines 2017
sepsis new guidelines 2017sepsis new guidelines 2017
sepsis new guidelines 2017
Dr. Mohamed Maged Kharabish
 
Septic shock Pathophysiology
Septic shock Pathophysiology Septic shock Pathophysiology
Septic shock Pathophysiology
Society for Microbiology and Infection care
 
Guidelines Sepsis(Power Point)
Guidelines Sepsis(Power Point)Guidelines Sepsis(Power Point)
Guidelines Sepsis(Power Point)gatotaji
 

Viewers also liked (20)

Principles of Antibiotic Use in ICU
Principles of Antibiotic Use in ICUPrinciples of Antibiotic Use in ICU
Principles of Antibiotic Use in ICU
 
Clindamycin
ClindamycinClindamycin
Clindamycin
 
Antibiotic update in icu
Antibiotic update in icuAntibiotic update in icu
Antibiotic update in icu
 
Guidelines for antibiotic use in icu
Guidelines for  antibiotic use in icuGuidelines for  antibiotic use in icu
Guidelines for antibiotic use in icu
 
Antibiotic principles
Antibiotic principlesAntibiotic principles
Antibiotic principles
 
Clindamycin
ClindamycinClindamycin
Clindamycin
 
New generation Antibiotics /certified fixed orthodontic courses by Indian den...
New generation Antibiotics /certified fixed orthodontic courses by Indian den...New generation Antibiotics /certified fixed orthodontic courses by Indian den...
New generation Antibiotics /certified fixed orthodontic courses by Indian den...
 
Detection of inducible and constitutive clindamycin resistance among Staphylo...
Detection of inducible and constitutive clindamycin resistance among Staphylo...Detection of inducible and constitutive clindamycin resistance among Staphylo...
Detection of inducible and constitutive clindamycin resistance among Staphylo...
 
Antibiotics
AntibioticsAntibiotics
Antibiotics
 
Clindamycine,,
Clindamycine,,Clindamycine,,
Clindamycine,,
 
Clindamycin
ClindamycinClindamycin
Clindamycin
 
Sedation in icu
Sedation in icuSedation in icu
Sedation in icu
 
Ppt penggunaan antibiotik yang bijaksana
Ppt penggunaan antibiotik yang bijaksanaPpt penggunaan antibiotik yang bijaksana
Ppt penggunaan antibiotik yang bijaksana
 
Levofloxacin
LevofloxacinLevofloxacin
Levofloxacin
 
Brain death in ICU
Brain death in ICUBrain death in ICU
Brain death in ICU
 
Optimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICUOptimal Antibiotic Strategies in ICU
Optimal Antibiotic Strategies in ICU
 
Sepsis seminar final
Sepsis seminar   finalSepsis seminar   final
Sepsis seminar final
 
sepsis new guidelines 2017
sepsis new guidelines 2017sepsis new guidelines 2017
sepsis new guidelines 2017
 
Septic shock Pathophysiology
Septic shock Pathophysiology Septic shock Pathophysiology
Septic shock Pathophysiology
 
Guidelines Sepsis(Power Point)
Guidelines Sepsis(Power Point)Guidelines Sepsis(Power Point)
Guidelines Sepsis(Power Point)
 

Similar to Antibiotics 2015 in icu

Antibiotics 2015 in icu
Antibiotics 2015 in icuAntibiotics 2015 in icu
Antibiotics 2015 in icu
Dr. Mohamed Maged Kharabish
 
Newer_Antibioticcccccccccccccccccccs.ppt
Newer_Antibioticcccccccccccccccccccs.pptNewer_Antibioticcccccccccccccccccccs.ppt
Newer_Antibioticcccccccccccccccccccs.ppt
DiptiPriya6
 
Anti TBs.pptx
Anti TBs.pptxAnti TBs.pptx
Anti TBs.pptx
KipronoKeitanyTimoth
 
Antibiotics
AntibioticsAntibiotics
Antibiotics
Dr Revathy Mohan
 
m4_hg_antibiotics (1).ppt
m4_hg_antibiotics (1).pptm4_hg_antibiotics (1).ppt
m4_hg_antibiotics (1).ppt
AnarghaNambiar
 
Antimicrobials.ppt
Antimicrobials.pptAntimicrobials.ppt
Antimicrobials.ppt
Prof. Dr Pharmacology
 
ANTIBIOTICS.ppt
ANTIBIOTICS.pptANTIBIOTICS.ppt
ANTIBIOTICS.ppt
IsmaelNdayisanga
 
Antibiotic therapy in the intensive care unit [autosaved]
Antibiotic therapy in the intensive care unit [autosaved]Antibiotic therapy in the intensive care unit [autosaved]
Antibiotic therapy in the intensive care unit [autosaved]Amrita Bhattacharyya
 
Antimicrobial drugs 2017
Antimicrobial drugs 2017Antimicrobial drugs 2017
Antimicrobial drugs 2017
Dr Md Abdullah Yusuf Sohel
 
Antibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract InfectionsAntibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract Infections
Gamal Agmy
 
Aminoglycoside and it's uses , side effect
Aminoglycoside and it's uses , side effectAminoglycoside and it's uses , side effect
Aminoglycoside and it's uses , side effect
TharikJack
 
Intracranial fungal INFECTIONS
Intracranial fungal INFECTIONSIntracranial fungal INFECTIONS
Intracranial fungal INFECTIONS
Ankit Jain
 
Drugs for tuberculosis
Drugs for tuberculosisDrugs for tuberculosis
Drugs for tuberculosis
Subramani Parasuraman
 
Superinfection
SuperinfectionSuperinfection
Superinfection
Dr. Pooja
 
Antibiotics classification ppt
Antibiotics classification pptAntibiotics classification ppt
Antibiotics classification ppt
ajengsekarkirana
 
Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)
BrahmjotKaur11
 
Antibiotics & analgesics dentistry
Antibiotics  & analgesics dentistryAntibiotics  & analgesics dentistry
Antibiotics & analgesics dentistry
Hema Latha
 

Similar to Antibiotics 2015 in icu (20)

Antibiotics 2015 in icu
Antibiotics 2015 in icuAntibiotics 2015 in icu
Antibiotics 2015 in icu
 
Newer_Antibioticcccccccccccccccccccs.ppt
Newer_Antibioticcccccccccccccccccccs.pptNewer_Antibioticcccccccccccccccccccs.ppt
Newer_Antibioticcccccccccccccccccccs.ppt
 
Vancomycin
VancomycinVancomycin
Vancomycin
 
Anti TBs.pptx
Anti TBs.pptxAnti TBs.pptx
Anti TBs.pptx
 
Antibiotics
AntibioticsAntibiotics
Antibiotics
 
m4_hg_antibiotics (1).ppt
m4_hg_antibiotics (1).pptm4_hg_antibiotics (1).ppt
m4_hg_antibiotics (1).ppt
 
Antimicrobials.ppt
Antimicrobials.pptAntimicrobials.ppt
Antimicrobials.ppt
 
ANTIBIOTICS.ppt
ANTIBIOTICS.pptANTIBIOTICS.ppt
ANTIBIOTICS.ppt
 
Antibiotic therapy in the intensive care unit [autosaved]
Antibiotic therapy in the intensive care unit [autosaved]Antibiotic therapy in the intensive care unit [autosaved]
Antibiotic therapy in the intensive care unit [autosaved]
 
Antimicrobial drugs 2017
Antimicrobial drugs 2017Antimicrobial drugs 2017
Antimicrobial drugs 2017
 
Aminoglycoside
AminoglycosideAminoglycoside
Aminoglycoside
 
Non resistant tuberculosis
Non resistant tuberculosisNon resistant tuberculosis
Non resistant tuberculosis
 
Antibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract InfectionsAntibiotic Strategy in Lower Respiratory Tract Infections
Antibiotic Strategy in Lower Respiratory Tract Infections
 
Aminoglycoside and it's uses , side effect
Aminoglycoside and it's uses , side effectAminoglycoside and it's uses , side effect
Aminoglycoside and it's uses , side effect
 
Intracranial fungal INFECTIONS
Intracranial fungal INFECTIONSIntracranial fungal INFECTIONS
Intracranial fungal INFECTIONS
 
Drugs for tuberculosis
Drugs for tuberculosisDrugs for tuberculosis
Drugs for tuberculosis
 
Superinfection
SuperinfectionSuperinfection
Superinfection
 
Antibiotics classification ppt
Antibiotics classification pptAntibiotics classification ppt
Antibiotics classification ppt
 
Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)Antitubercular drugs (ATT drugs)
Antitubercular drugs (ATT drugs)
 
Antibiotics & analgesics dentistry
Antibiotics  & analgesics dentistryAntibiotics  & analgesics dentistry
Antibiotics & analgesics dentistry
 

More from samirelansary

Delerium in icu
Delerium in icuDelerium in icu
Delerium in icu
samirelansary
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
samirelansary
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
samirelansary
 
Ventricular tachycardia
Ventricular tachycardiaVentricular tachycardia
Ventricular tachycardia
samirelansary
 
Gaps in acid base balance in icu
Gaps in acid base balance in icuGaps in acid base balance in icu
Gaps in acid base balance in icu
samirelansary
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
samirelansary
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
samirelansary
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
samirelansary
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
samirelansary
 
Arterial line analysis
Arterial line analysisArterial line analysis
Arterial line analysis
samirelansary
 
X.ray pearls 1
X.ray pearls  1X.ray pearls  1
X.ray pearls 1
samirelansary
 
Update in infectious diseases 1
Update in infectious diseases 1Update in infectious diseases 1
Update in infectious diseases 1
samirelansary
 
Subarachnoid haemorrhage
Subarachnoid haemorrhageSubarachnoid haemorrhage
Subarachnoid haemorrhage
samirelansary
 
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and managementSYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
samirelansary
 
Serotonin syndrome 2
Serotonin syndrome  2Serotonin syndrome  2
Serotonin syndrome 2
samirelansary
 
Principles of mechanical ventilation 2
Principles of mechanical ventilation  2Principles of mechanical ventilation  2
Principles of mechanical ventilation 2
samirelansary
 
New critical care issues 2015 17
New critical care issues 2015 17New critical care issues 2015 17
New critical care issues 2015 17
samirelansary
 
Mixed connective tissue disease
Mixed connective tissue diseaseMixed connective tissue disease
Mixed connective tissue disease
samirelansary
 
Intracranial pressure 2015
Intracranial pressure  2015Intracranial pressure  2015
Intracranial pressure 2015
samirelansary
 
Icu research points 2015 1
Icu research points 2015   1Icu research points 2015   1
Icu research points 2015 1
samirelansary
 

More from samirelansary (20)

Delerium in icu
Delerium in icuDelerium in icu
Delerium in icu
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
 
Ventricular tachycardia
Ventricular tachycardiaVentricular tachycardia
Ventricular tachycardia
 
Gaps in acid base balance in icu
Gaps in acid base balance in icuGaps in acid base balance in icu
Gaps in acid base balance in icu
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
 
Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)Colistin colistin (polymyxin e)
Colistin colistin (polymyxin e)
 
Chest x. ray interpretation and teaching
Chest x. ray interpretation and teachingChest x. ray interpretation and teaching
Chest x. ray interpretation and teaching
 
Cerebral monitoring
Cerebral monitoringCerebral monitoring
Cerebral monitoring
 
Arterial line analysis
Arterial line analysisArterial line analysis
Arterial line analysis
 
X.ray pearls 1
X.ray pearls  1X.ray pearls  1
X.ray pearls 1
 
Update in infectious diseases 1
Update in infectious diseases 1Update in infectious diseases 1
Update in infectious diseases 1
 
Subarachnoid haemorrhage
Subarachnoid haemorrhageSubarachnoid haemorrhage
Subarachnoid haemorrhage
 
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and managementSYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
SYSTEMIC LUPUS ERYTHEMATOSUS Sle pathophysiology and management
 
Serotonin syndrome 2
Serotonin syndrome  2Serotonin syndrome  2
Serotonin syndrome 2
 
Principles of mechanical ventilation 2
Principles of mechanical ventilation  2Principles of mechanical ventilation  2
Principles of mechanical ventilation 2
 
New critical care issues 2015 17
New critical care issues 2015 17New critical care issues 2015 17
New critical care issues 2015 17
 
Mixed connective tissue disease
Mixed connective tissue diseaseMixed connective tissue disease
Mixed connective tissue disease
 
Intracranial pressure 2015
Intracranial pressure  2015Intracranial pressure  2015
Intracranial pressure 2015
 
Icu research points 2015 1
Icu research points 2015   1Icu research points 2015   1
Icu research points 2015 1
 

Recently uploaded

Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 

Recently uploaded (20)

Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 

Antibiotics 2015 in icu

  • 4. Definitions • Minimum Inhibitory Concentration – Antimicrobial concentration that inhibits visible microbial growth in artificial media • Gram Stain – Gram positive – Gram negative • Acid fast
  • 5. • Problems with MIC: •Fixed drug concentration •All or none parameter. Growth vs. no growth •Does not provide information on the time course of antimicrobial activity •Drug concentrations change throughout the dosing interval •Does not capture interpatient pharmacokinetic variability •Does not provide info on post-antibiotic effects
  • 6. Gram staining FOR differentiating bacterialspecies into (gram- positive and gram-negative). The name comes from its inventor, Hans Christian Gram. Gram staining differentiates bacteria by the chemical and physical properties of their cell walls by detecting peptidoglycan, which is present in a thick layer in gram-positive bacteria.
  • 7. Gram staining In a Gram stain test, gram-positive bacteria retain the crystal violet dye, while a counterstain (commonly safranin or fuchsine) added after the crystal violet gives all gram-negative bacteria a red or pink coloring.
  • 8. Acid-fastness A physical property of certain bacteria (and, less commonly, protozoa), specifically their resistance to decolorization by acids during staining procedures. The high mycolic acid content of certain Protozoa cell walls, and those of Mycobacteria, is responsible for the staining pattern of poor absorption followed by high retention. Usually used to identify mycobacteria.
  • 9. Pharmacodynamics Time Dependent Killing • Beta-Lactams – Penicillin – Cephalosporins – Piperacillin-Tazobactam – Carbapenems • Meropenem • Ertapenem
  • 10. • Pharmacokinetics versus pharmacodynamics •Pharmacokinetics mathematically describe the relationship of antibiotic concentration to time. • Aabsorption, distribution, metabolism, elimination, half-life, volume of distribution, and area under the concentration-time curve (AUC).
  • 11. •Pharmacodynamics •Describe the relationship of antibiotic concentration to pharmacologic effect or microorganism death. • The three main pharmacodynamic parameters that are used are the • peak to minimal inhibitory concentration ratio (peak/MIC), the AUC to MIC ratio (AUC/MIC)
  • 12. •Pharmacodynamics • The time the drug concentration remains above the MIC (T>MIC). • Concentration independent antimicrobials include: beta- lactams, vancomycin, macrolides, aztreonam, carbapenems, clindamycin, tetracyclines, quinupristin/dalfopristin, flucytosine, and azole antifungals.
  • 13. Pharmacodynamics Concentration Dependent Killing • Fluoroquinolones – Levofloxacin – Ciprofloxacin – Moxifloxacin • Aminoglycosides – Amikacin – Tobramycin – Gentamicin
  • 14. Pharmacodynamics AUC/MIC Dependent Killing • Vancomycin • Linezolid • Clindamycin • Macrolides – Azithromycin – Clarithromycin – Erythromycin
  • 15. Keys to Success • Antibiotic covers potential infection/bacteria • Dose of antibiotic is appropriate for treatment of infection and adjusted for renal/hepatic impairment • Antibiotic penetrates site of infection • Antibiotic is being absorbed • Adequate treatment duration
  • 16. Risk Factors for Resistance • Antimicrobial therapy in the preceding 90 days • Current hospitalization of 5 days or more • High resistance rates in the unit • Residence in a nursing home or extended care facility • Immunocompromised • Home wound care • Chronic dialysis
  • 18. Gram Positive Bacteria • Cocci – Staphylococcus • S. aureus • S. epidermidis – Streptococcus • S. pyogenes (Group A) • S. viridians • S. pneumoniae – Enterococcus • E. faecalis • E. Faecium • Bacilli – Listeria monocytogenes – Bacillus anthracis – Corynebacterium species – Proprionibacterium acnes
  • 19. Vancomycin • Spectrum of activity – Staph (MRSA, MSSA), strep, enterococcus, c. difficile colitis (oral) • Mechanism of action – Inhibits synthesis of peptidoglycan/bacterial cell wall formation • Dosing – Actual body weight – Loading dose = 25-30 mg/kg – Maintenance dose = 15-20 mg/kg – Usual Frequency = every 8-24h – Adjust dose for renal impairment
  • 20. Vancomycin • Adverse effects – Redman syndrome – Thrombocytopenia – Possible nephrotoxicity ?? – Ototoxicity (rare) Ototoxicity is not associated with trough concentrations. • Monitoring – Goal Trough = 15-20 mcg/mL – Bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia – Initial: trough before 4th or 5th dose – Maintenance: trough once weekly
  • 21. Vancomycin with Dialysis • Continuous renal replacement therapy (CRRT) – 15mg/kg q24h – Hold dose if CRRT stopped > 8h – Trough before 4th or 5th dose • Intermittent hemodialysis (iHD) – Pulse dosing with iHD – iHD removes ~25% of vancomycin – Goal Pre-iHD level < 24 mcg/mL – Initial dose = 15mg/kg x1 dose – Maintenance dose based on pre-iHD levels
  • 22. Linezolid • Spectrum of activity – Staph (MSSA, MRSA), strep, VRE • Mechanism of action – Binds to bacterial ribosomes to inhibit protein synthesis • Bacteristatic against staph, vre but cidal against strep pneumon • Time dependent killing
  • 23. Linezolid • Adverse Effects – Myelosupression (pancytopenia, thrombocytopenia) – GI upset – Serotonin syndrome • Drug interactions – Monoamine oxidase inhibitors (MAOI’s) – Selective serotonin reuptake inhibitors (SSRI’s) • Dosing – 600mg IV/PO q12h
  • 24. Linezolid • Clinical Pearls – May be used for vancomycin failure or intolerance – Oral & IV formulations – Bacteriostatic – No renal adjustment – May have prescribing restrictions – Expensive
  • 25. Daptomycin • Spectrum of activity – Staph (MSSA, MRSA), strep, enterococcus (VRE) • Mechanism of action – Causes bacterial membranes to depolarize leading to inhibition of protein, DNA, and RNA synthesis • Typical Dosing – Adjust with renal impairment – 4-6 mg/kg (actual weight) q24-48h • Adverse Effects – Arthralgia – Myalgia – CPK elevations
  • 26. Daptomycin • Clinical Pearls – Not for treatment of pneumonia – Can use doses of 8-10 mg/kg for severe infections – Monitor CPK at baseline and weekly – Can falsely elevate INR – May have prescribing restrictions – Takes 30-60 minutes to reconstitute – Expensive
  • 28. Gram Negative Bacteria Cocci • Neisseria gonorrhoeae • Neisseria meningitidis • Moraxella catarrhalis Bacilli • Pseudomonas aeruginosa • Acinetobacter species • Citrobacter species • Enterobacter species • Klebsiella pneumoniae • E. Coli • H. influenzae • Proteus mirabilis • S. maltophilia
  • 30. Aminoglycosides • Spectrum of activity – Only gram negative, gram positive synergy • Mechanism of action – Bind bacterial ribosome and inhibit protein synthesis • Adverse effects – Nephrotoxicity – Ototoxicity – Prolonged neuromuscular blockade Medications Gentamicin Tobramycin Amkicacin
  • 31. • Aminoglycoside antibiotics possess nondepolarizing neuromuscular blocking activity, which is additive or synergistic with the effects of the nondepolarizing neuromuscular blocking agents used in anesthesia . • Aminoglycosides cause presynaptic inhibition of acetylcholine release and postsynaptic reduction in sensitivity
  • 32. Aminoglycosides • Clinical Pearls – Used for • Nosocomial infections • Double gram negative coverage • Endocarditis (synergy) – Two dosing schemes • Traditional dosing • Extended interval dosing/once daily dosing – Levels must be monitored • Traditional = peak & trough around 3rd dose • Extended interval = trough before 2nd dose – Monitor Scr daily
  • 33. Aztreonam • Class – Monobactam • Spectrum of activity ‒ Gram positive: none ‒ Gram negative: most, except S. maltophilia • Mechanism of action – Inhibit cell wall synthesis • Dosing – Usual: 1-2g IV Q8h – Meningitis: 2g IV Q6-8h • Adverse effects (rare) – Transient eosinophilia – LFT elevations – Thrombocytopenia **Can be used with penicillin allergy**
  • 35. Spectrum of Activity Primary Use First Generation Cefazolin (Ancef) (IV) Cephalexin (Keflex) (PO) • Simple Gram (+) , simple gram (-) , no anaerobes. No ceph gets enterococci. • Simple SSTI, surgical prophylaxis Second Generation Cefotetan (Cefotan) (IV) Cefoxitin (Mefoxin) (IV) Cefuroxime (Ceftin) (IV) Cefaclor (Ceclor) (PO) Cefprozil (Cefzil) (PO) • Same spectrum as 1st Generation • Cefotetan and Cefoxitin cover anaerobes • Surgical prophylaxis if anaerobes, URTI, UTI Third Generation Ceftriaxone (Rocephin) (IV) Cefotaxime (Claforan) (IV) Ceftazadime (Fortaz) (IV) Cefpodoxime (Vantan) (PO) Cefdinir (Omnicef) (PO) Cefixime (Suprax) (PO) • Better gram (-) • Ceftazadime-pseudomonas • PNA, meningitis Fourth Generation Cefepime (Maxipime) (IV) • Good gram (+), nosocomial gram (-) including pseudomonas • No anaerobes • Sepsis, HAP, neutropenic fever Fifth Generation Ceftaroline (Teflaro) • MRSA, MSSA, E. faecalis, s.pneumoniae, • Some gram (-), NO pseudomonas • Pneumonia, SSTI Cephalosporins
  • 36. • CABP pathogens, ceftaroline has activity against the Gram-positive organisms S. pneumoniae, S. aureus and Streptococcus pyogenes, and Gram-negative species (Haemophilus influenzae and CABP pathogens, ceftaroline has activity against the Gram-positive organisms S. pneumoniae, S. aureus and Streptococcus pyogenes, and Gram-negative species .
  • 37. Cephalosporins • Clinical Pearls – Do not cover enterococcus (except ceftaroline) – ↑ gram negative coverage with higher generations – Used for surgical prophylaxis – Anaerobic coverage • Cefoxitin • Cefotetan – Pseudomonas coverage • Ceftazidime • Cefepime
  • 38. Fluoroquinolines Medications Ciprofloxaci n Levofloxacin Moxifloxacin Gemifloxaci n Mechanism of Action Inhibit DNA gyrase and topoisomerase IV inhibiting DNA synthesis Spectrum of Activity • Gram Negative: Enterobacteriaceae, Haemophilus spp, Neisseria spp and M. Catarrhalis • Atypicals Pseudomonas Pseudomonas S. pneumoniae Anaerobes S. pneumoniae - - - Clinical Use Gram (-) infections, Bone/Joint PNA, UTI PNA NOT: UTI PNA
  • 39. Piperacillin-Tazobactam • Spectrum of activity – Gram negative: P. aeruginosa, Enterbacteriaceae – Gram positive: MSSA, Enterococci, Strep – Anaerobes • Mechanism of action – Inhibit cell wall synthesis • Adverse effects – Gastrointestinal intolerance – C. difficle colitis – Interstitial nephritis
  • 40. • Mechanism of Action: •Inhibit mucopeptide synthesis in the bacterial cell wall, thus results in formation of defective cell walls and osmotically unstable organisms susceptible to cell lysis •Tazobactam acts as a beta-lactamase inhibitor and inactivates both plasmid and chromosome mediated beta-lactamases
  • 41. Carbapenems Meropenem (Merem®) Ertapenem (Invanz®) Imipenem - Cilastatin (Primaxin®) Doripenem (Doribax®) Mechanism of Action Inhibit cell wall synthesis Spectrum of Activity Broad Spectrum: Gram (+), Gram (-), ESBL, Anaerobes NOT: MRSA -- NOT: Pseudomonas, Enterococcus, Acinetobacter -- -- Adverse Effects ↓ Platelets Drug Fever Seizure ↓ Platelets Drug Fever Common Use Meningitis Intra-abdominal Nocardia NOT: Pneumonia
  • 42. Carbapenems • Clinical Pearls – First line agent for extended spectrum beta-lactamase (ESBL) producing bacteria – Extended infusion meropenem • ↑ time above MIC – Reserved for severe infections – May have prescribing restrictions
  • 43. Tigecycline • Spectrum of activity – Enterococcus (including VRE), MSSA, MRSA, MRSE, anaerobes – Not pseudomonas, proteus, providencia • Mechanism of action – Binds to bacterial ribosomes to inhibit protein synthesis • Dose – 100mg IV x 1 dose – 50mg IV q12h • Adverse effects – Nausea and vomiting – Hyperbiliruminemia
  • 44. •Tigecycline has a spectrum of activity that includes anaerobes, many gram- positive cocci and gram-negative bacilli w/ the exception of Pseudomonas, Proteus, and Providencia. •N/V may occur in up to 2/3rds of patients
  • 45. Tigecycline • Clinical Pearls – No renal adjustment – Hepatic dose adjustment (Child Pugh C) • 100mg IV x 1, then 25mg IV Q12h – Used for resistant infections – Do not use for • Ventilator associated pneumonia • Bacteremia – Can be used for • Intra-abdominal infections • Skin & soft tissue infections
  • 46. •All-cause Mortality: •An increase in all-cause mortality has been observed •The cause of this mortality risk difference has not been established. •Tigecycline should be reserved for use in situations when alternative treatments are not suitable. •Death resulted from progression of infection •Especially in ventilator associated pneumonia •Reserve for use when other agents are not an option
  • 48. Atypical Bacteria Agents • Fluoroquinolones – Levofloxacin – Ciprofloxacin – Moxifloxacin – Gemifloxacin • Macrolides – Azithromycin – Erythromycin – Clarithromycin • Tetracyclines – Tetracycline – Doxycycline – Minocycline Bacteria • Mycoplasma • Legionella pneumoniae • Chlamydia pneumoniae • Richettsia • Actinomyces
  • 51. Clostridium Difficile • IDSA Recommendations – No probiotics - ↑ Bloodstream infections – Stop causative antimicrobials – Repeat testing during the same episode is discouraged – Vancomycin taper after second reoccurrence – Dual antimicrobials • Ileus = IV metronidazole + vancomycin enema **PO vancomycin is only used to treat c. diff infection**
  • 52. • There is no evidence to support administration of combination therapy to patients with uncomplicated CDI. • Although hampered by its low statistical power, a recent trial did not show any trend toward better results when rifampin was added to a metronidazole regimen. • There is no evidence to support use of a combination of oral metronidazole and oral vancomycin.
  • 53. Allergic Reactions • IgE reactions – Anaphylaxis – Bronchospasm – Angioedema – Pruritic rash – Uticaria – Hypotension
  • 54. Penicillin Allergy Avoid Use Incidence of Reaction May Use Cephalosporins • 1st/2nd generation cephalosporin 2% • Aztreonam • 3rd/4th generation cephalosporin Carbapenems • None? 0-11% • All carbapenems? • Aztreonam • Graded challenge or PCN skin test
  • 55. •Penicillin-cephalosporin cross-reactivity studies that confirmed penicillin allergy by skin testing are superior in design compared with those that diagnosed penicillin allergy by history alone. •Another group of studies evaluated patients with positive penicillin skin tests (to penicilloyl polylysine [PPL], penicillin G, and/or the minor determinant mixture [MDM]) who were challenged with cephalosporins and found an overall reaction rate of 3.4 percent .
  • 56. •If this analysis is limited to studies published after 1980 (when cephalosporins were no longer contaminated with penicillin), the reaction rate is reduced to 2 percent. •Thus, approximately 2 percent of patients with skin- test proven sensitivity to penicillin can be expected to react to cephalosporins. •Range for cephalosporin reaction was 0-12% reported in the literature.
  • 58. GOOD LUCK SAMIR EL ANSARY ICU PROFESSOR AIN SHAMS CAIRO elansarysamir@yahoo.com Global Critical Care https://www.facebook.com/groups/1451610115129555/#!/groups/145 1610115129555/ Wellcome in our new group ..... Dr.SAMIR EL ANSARY

Editor's Notes

  1. Pharmacokinetics versus pharmacodynamics Pharmacokinetics mathematically describe the relationship of antibiotic concentration to time. Terminology that is typically associated with pharmacokinetics includes: absorption, distribution, metabolism, elimination, half-life, volume of distribution, and area under the concentration-time curve (AUC). Pharmacodynamics describe the relationship of antibiotic concentration to pharmacologic effect or microorganism death. The three main pharmacodynamic parameters that are used are the peak to minimal inhibitory concentration ratio (peak/MIC), the AUC to MIC ratio (AUC/MIC), and the time the drug concentration remains above the MIC (T>MIC). concentration independent antimicrobials include: beta-lactams, vancomycin, macrolides, aztreonam, carbapenems, clindamycin, tetracyclines, quinupristin/dalfopristin, flucytosine, and azole antifungals.
  2. Mycoplasma vs. mycobacteria Clinical Pearls Uses Community acquired pneumonia Opportunistic infections Tic born illness COPD exacerbations